Holen Sie sich die Stockscreener-App
2.016
3.92%
0.076
Schlusskurs vom Vortag:
$1.94
Offen:
$1.95
24-Stunden-Volumen:
8,002
Relative Volume:
0.18
Marktkapitalisierung:
$7.82M
Einnahmen:
$20,000
Nettoeinkommen (Verlust:
$-10.84M
KGV:
-0.7237
EPS:
-2.7857
Netto-Cashflow:
$-10.07M
1W Leistung:
+6.67%
1M Leistung:
+1.82%
6M Leistung:
-26.43%
1J Leistung:
-23.22%
1-Tages-Spanne:
$1.9222
$1.99
1-Wochen-Bereich:
$1.84
$1.99
52-Wochen-Spanne:
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Firmenname
Kiora Pharmaceuticals Inc
Sektor
Branche
Telefon
858-224-9600
Adresse
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
1.98 | 7.66M | 20,000 | -10.84M | -10.07M | -2.7857 |
VRTX
Vertex Pharmaceuticals Inc
|
433.58 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.40 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.74 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Kiora Pharmaceuticals Inc Aktie (KPRX) Neueste Nachrichten
Critical Outcome Technologies (OTCMKTS:COTQF) and Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Survey - Defense World
Kiora Pharmaceuticals Announces Chief Development Officer Resignation - TipRanks
Kiora Pharmaceuticals chief development officer to depart - Investing.com
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora Pharmaceuticals (KPRX) CFO uses 929 shares to cover taxes - Stock Titan
Kiora (NASDAQ: KPRX) executive uses 929 shares to satisfy tax withholding - Stock Titan
Kiora (KPRX) CEO withholds 1,906 shares to cover stock taxes - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) details CDO exit and trial progress - Stock Titan
Kiora says retinal disease trials keep enrolling after exec exit - Stock Titan
KPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Will Kiora Pharmaceuticals Inc outperform its industry peersProduct Launch & Safe Entry Zone Identification - baoquankhu1.vn
Should I hold or sell Kiora Pharmaceuticals Inc nowQuarterly Market Review & Accurate Trade Setup Notifications - baoquankhu1.vn
Kiora Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Kiora Pharmaceuticals reports $10.8M loss for 2025 By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Bitget
Kiora Pharmaceuticals reports $10.8M loss for 2025 - Investing.com
Kiora Pharmaceuticals posts 2025 net loss as expenses rise - TradingView
Kiora Pharmaceuticals 10-K: $0M Revenue, $(10.84)M Net Loss - TradingView
Kiora (NASDAQ: KPRX) posts 2025 loss while funding two active Phase 2 trials - Stock Titan
Retinal disease pipeline at Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan
Two retinal disease trials underway as Kiora says cash lasts into 2027 - Stock Titan
If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX) - Stock Titan
Sectors Review: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Trends & AI Driven Stock Reports - baoquankhu1.vn
KPRX Should I Buy - Intellectia AI
Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (NASDAQ: KPRX) CFO granted new stock and option awards - Stock Titan
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Kiora Pharmaceuticals (KPRX) CDO uses 238 shares to cover tax withholding - Stock Titan
Kiora Pharmaceuticals (KPRX) CEO disposes 238 shares for taxes - Stock Titan
KPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Fear: Can Kiora Pharmaceuticals Inc keep up with sector leadersRisk Management & Technical Pattern Based Signals - baoquankhu1.vn
KPRXKIORA PHARMACEUTICALS INC Latest Stock News & Market Updates - Stock Titan
Retail Trends: Is Kiora Pharmaceuticals Inc a defensive stockWeekly Trend Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
What is Kiora Pharmaceuticals Inc. s debt to equity ratioIPO Watch & Community Verified Swing Trade Signals - mfd.ru
SEC EDGAR Submission 0001104659-22-079906 - SEC.gov
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - TMX Newsfile
KPRX Technical Analysis & Stock Price Forecast - Intellectia AI
KPRX PE Ratio & Valuation, Is KPRX Overvalued - Intellectia AI
Can Kiora Pharmaceuticals Inc. stock hit record highs againMarket Sentiment Summary & Entry Point Confirmation Alerts - mfd.ru
Weekly Earnings: Whats the profit margin of Kiora Pharmaceuticals IncJuly 2025 Short Interest & Weekly High Return Stock Opportunities - baoquankhu1.vn
Comparing Kiora Pharmaceuticals (NASDAQ:KPRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN) - Defense World
Quarterly Earnings: Can MicroSectors Gold Miners 3X Leveraged ETNs due June 29 2040 continue delivering strong returnsTrend Reversal & Target Return Focused Picks - baoquankhu1.vn
Volatility Watch: Is Kiora Pharmaceuticals Inc a defensive stockBond Market & Daily Entry Point Trade Alerts - baoquankhu1.vn
Is Kiora Pharmaceuticals Inc still a buy after recent gains2025 Technical Patterns & Expert Verified Movement Alerts - baoquankhu1.vn
Kiora Pharmaceuticals adds retina specialist to advisory board By Investing.com - Investing.com Canada
Why a leading retinal surgeon is backing new non-steroid eye drugs - Stock Titan
Update Recap: Does Kiora Pharmaceuticals Inc have pricing power2025 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Trade Recap: Does Kiora Pharmaceuticals Inc have consistent dividend growthMarket Risk Report & Growth-Oriented Investment Plans - baoquankhu1.vn
Can Kiora Pharmaceuticals Inc. stock surprise with earnings upsideDividend Aristocrats List & Outperform With Our Smart Trading Calculator - Bollywood Helpline
Institution Moves: Can ADS TEC Energy PLC Equity Warrant deliver alphaEarnings Growth Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Finanzdaten der Kiora Pharmaceuticals Inc-Aktie (KPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):